id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0002,FDA,FDA-2014-D-1167,Draft Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Other,Guidance,2014-08-27T04:00:00Z,2014,8,2014-08-27T04:00:00Z,,2019-06-18T16:45:19Z,,0,0,09000064818483c9
FDA-2014-D-1167-0001,FDA,FDA-2014-D-1167,"Draft Guidance for Industry on Controlled Correspondence Related to
Generic Drug Development; Availability",Notice,Notice of Availability,2014-08-27T04:00:00Z,2014,8,2014-08-27T04:00:00Z,2014-10-28T03:59:59Z,2015-09-12T01:31:10Z,2014-20359,0,0,0900006481847bfd